Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.

Magnusson P, Degerblad M, Sääf M, Larsson L, Thorén M

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Feb 1997Cited by 52 (Europe PMC)

PMID9041052DOI10.1359/jbmr.1997.12.2.210PepBankPUB-09041052

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, GH therapy decreased bone ALP isoform B1 after 1 month versus baseline.
In plain wordsIn adults with GH deficiency, GH decreased bone ALP isoform B1 after 1 month versus baseline.
Peptide
HGH (somatotropin)
Outcome
DecreaseBone ALP B1 after 1 month
Study
n = 20
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg/week · 1 monthAs given in this study (human).
Source sentences
Summary
After 2 week of IGF-I administration and 1 month of GH therapy, only B1 was decreased.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied serum bone alkaline phosphatase (ALP) isoforms and other markers of bone turnover in growth hormone-deficient (GHD) adults (n = 22).
Summary · context
The patients were followed during 1 week of insulin-like growth factor-I (IGF-I) administration, 40 micrograms/kg of body weight/day (n = 6), and during 24 months of growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, and then 0.250 IU/kg of body weight/week (n = 20).
Report a problemFND-0904105202
02HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, osteocalcin increased during GH therapy versus baseline.
In plain wordsIn adults with GH deficiency, osteocalcin increased during GH therapy versus baseline.
Peptide
HGH (somatotropin)
Outcome
IncreaseOsteocalcin
Study
n = 20
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg/week for the first month, then 0.250 IU/kg/weekAs given in this study (human).
Source sentences
Summary
Osteocalcin, carboxy-terminal propeptide of type I procollagen (PICP), cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), and urinary pyridinoline cross-links/creatinine ratio increased during GH therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied serum bone alkaline phosphatase (ALP) isoforms and other markers of bone turnover in growth hormone-deficient (GHD) adults (n = 22).
Summary · context
The patients were followed during 1 week of insulin-like growth factor-I (IGF-I) administration, 40 micrograms/kg of body weight/day (n = 6), and during 24 months of growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, and then 0.250 IU/kg of body weight/week (n = 20).
Report a problemFND-0904105205
03HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, PICP increased during GH therapy versus baseline.
In plain wordsIn adults with GH deficiency, the collagen marker PICP increased during GH therapy versus baseline.
Peptide
HGH (somatotropin)
Outcome
IncreasePICP
Study
n = 20
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg/week for the first month, then 0.250 IU/kg/weekAs given in this study (human).
Source sentences
Summary
Osteocalcin, carboxy-terminal propeptide of type I procollagen (PICP), cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), and urinary pyridinoline cross-links/creatinine ratio increased during GH therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied serum bone alkaline phosphatase (ALP) isoforms and other markers of bone turnover in growth hormone-deficient (GHD) adults (n = 22).
Summary · context
The patients were followed during 1 week of insulin-like growth factor-I (IGF-I) administration, 40 micrograms/kg of body weight/day (n = 6), and during 24 months of growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, and then 0.250 IU/kg of body weight/week (n = 20).
Report a problemFND-0904105206
04HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, ICTP increased during GH therapy versus baseline.
In plain wordsIn adults with GH deficiency, the collagen marker ICTP increased during GH therapy versus baseline.
Peptide
HGH (somatotropin)
Outcome
IncreaseICTP
Study
n = 20
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg/week for the first month, then 0.250 IU/kg/weekAs given in this study (human).
Source sentences
Summary
Osteocalcin, carboxy-terminal propeptide of type I procollagen (PICP), cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), and urinary pyridinoline cross-links/creatinine ratio increased during GH therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied serum bone alkaline phosphatase (ALP) isoforms and other markers of bone turnover in growth hormone-deficient (GHD) adults (n = 22).
Summary · context
The patients were followed during 1 week of insulin-like growth factor-I (IGF-I) administration, 40 micrograms/kg of body weight/day (n = 6), and during 24 months of growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, and then 0.250 IU/kg of body weight/week (n = 20).
Report a problemFND-0904105207
05HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, urinary pyridinoline cross-links/creatinine ratio increased during GH therapy versus baseline.
In plain wordsIn adults with GH deficiency, the urine pyridinoline cross-links/creatinine ratio increased during GH therapy versus baseline.
Peptide
HGH (somatotropin)
Outcome
IncreaseUrinary pyridinoline cross-links/creatinine ratio
Study
n = 20
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg/week for the first month, then 0.250 IU/kg/weekAs given in this study (human).
Source sentences
Summary
Osteocalcin, carboxy-terminal propeptide of type I procollagen (PICP), cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), and urinary pyridinoline cross-links/creatinine ratio increased during GH therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied serum bone alkaline phosphatase (ALP) isoforms and other markers of bone turnover in growth hormone-deficient (GHD) adults (n = 22).
Summary · context
The patients were followed during 1 week of insulin-like growth factor-I (IGF-I) administration, 40 micrograms/kg of body weight/day (n = 6), and during 24 months of growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, and then 0.250 IU/kg of body weight/week (n = 20).
Report a problemFND-0904105208
06HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, PICP increased significantly before bone ALP and osteocalcin during GH therapy.
In plain wordsIn adults with GH deficiency, PICP increased significantly before bone ALP and osteocalcin during GH therapy.
Peptide
HGH (somatotropin)
Outcome
Not applicableTiming of PICP increase
Study
n = 20
Comparator
Bone ALP and osteocalcin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg/week for the first month, then 0.250 IU/kg/weekAs given in this study (human).
Source sentences
Summary
PICP increased significantly before bone ALP and osteocalcin, indicating early stimulation of type I collagen synthesis as previously demonstrated by in vitro models.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied serum bone alkaline phosphatase (ALP) isoforms and other markers of bone turnover in growth hormone-deficient (GHD) adults (n = 22).
Summary · context
The patients were followed during 1 week of insulin-like growth factor-I (IGF-I) administration, 40 micrograms/kg of body weight/day (n = 6), and during 24 months of growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, and then 0.250 IU/kg of body weight/week (n = 20).
Report a problemFND-0904105209
07HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, bone ALP B1 decreased after IGF-I administration.
In plain wordsIn GH-deficient adults, the bone marker B1 decreased after IGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseBone ALP B1
Study
n = 6
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 micrograms/kg of body weight/day · 1 week of IGF-I administration (the result sentence says 2 week)As given in this study (human).
Source sentences
Summary
After 2 week of IGF-I administration and 1 month of GH therapy, only B1 was decreased.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied serum bone alkaline phosphatase (ALP) isoforms and other markers of bone turnover in growth hormone-deficient (GHD) adults (n = 22).
Summary · context
The patients were followed during 1 week of insulin-like growth factor-I (IGF-I) administration, 40 micrograms/kg of body weight/day (n = 6), and during 24 months of growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, and then 0.250 IU/kg of body weight/week (n = 20).
Report a problemFND-0904105201
08HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, GH therapy increased bone ALP isoform B1 after 3 months compared with placebo.
In plain wordsIn adults with GH deficiency, GH increased bone ALP isoform B1 after 3 months compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseBone ALP B1 after 3 months
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg/week for the first month, then 0.250 IU/kg/week · 3 monthsAs given in this study (human).
Source sentences
Summary
After 3 months of GH therapy, both B1 and B2 increased as compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied serum bone alkaline phosphatase (ALP) isoforms and other markers of bone turnover in growth hormone-deficient (GHD) adults (n = 22).
Summary · context
The patients were followed during 1 week of insulin-like growth factor-I (IGF-I) administration, 40 micrograms/kg of body weight/day (n = 6), and during 24 months of growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, and then 0.250 IU/kg of body weight/week (n = 20).
Report a problemFND-0904105203
09HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, GH therapy increased bone ALP isoform B2 after 3 months compared with placebo.
In plain wordsIn adults with GH deficiency, GH increased bone ALP isoform B2 after 3 months compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseBone ALP B2 after 3 months
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.125 IU/kg/week for the first month, then 0.250 IU/kg/week · 3 monthsAs given in this study (human).
Source sentences
Summary
After 3 months of GH therapy, both B1 and B2 increased as compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied serum bone alkaline phosphatase (ALP) isoforms and other markers of bone turnover in growth hormone-deficient (GHD) adults (n = 22).
Summary · context
The patients were followed during 1 week of insulin-like growth factor-I (IGF-I) administration, 40 micrograms/kg of body weight/day (n = 6), and during 24 months of growth hormone (GH) therapy, 0.125 IU/kg of body weight/week for the first month, and then 0.250 IU/kg of body weight/week (n = 20).
Report a problemFND-0904105204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.